Alimera Sciences (ALIM) Misses Q2 EPS by 133c

Alimera Sciences (NASDAQ: ALIM) reported Q2 EPS of ($1.32), $1.33 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $17.5 million versus the consensus estimate of $20.47 million.

For earnings history and earnings-related data on Alimera Sciences (ALIM) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c